Compare Wahed FTSE USA Shariah ETF (HLAL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.95, while Regeneron Pharmaceuticals Inc trades at $794.71 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals.
| HLAL | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $812.27 |
52-Week Low | $55.52 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $73.11 with a slight 0.19% daily gain, showing bullish technical momentum with strong moving average support. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data, and a small dividend of $0.02 is scheduled for June 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautiously optimistic given bullish technical trends, but limited fundamental data and high RSI levels near 95 warrant monitoring. Key risks include reliance on technical momentum without clear valuation anchors, while institutional sentiment appears constructive based on moving average alignment.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
